| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Proceeds from at-the-market sales agreement, net of commissions and allocated fees | 0 | 0 |
| Net cash provided by financing activities | 120,729 | 119,100 |
| Net increase (decrease) in cash and cash equivalents | 22,772 | 82,961 |
| Cash and cash equivalents at beginning of period | 34,097 | - |
| Cash and cash equivalents at end of period | 56,869 | - |
Trevi Therapeutics, Inc. (TRVI)
Trevi Therapeutics, Inc. (TRVI)